Cadila Healthcare Ltd. is in Pharmaceuticals & Drugs. It was incorporated in year 1995. The current market capitalisation stands Rs 22282 Cr. The company is listed on the Bombay Stock Exchange (BSE) with the BSE code as 532321. and also listed on National Stock Exchange (NSE) with NSE code as CADILAHC.
Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The offers products in the therapeutic areas of cardiovascular, gastro intestinal, respiratory, gynecology, pain management, dermatology, anti-infective, women’s healthcare, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the is developing 21 biosimilars and 6 novel products; and new drugs in cardio-metabolic disorder, inflammation, pain, and oncology and infectious diseases. Further, it engages in the retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.
Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing.
Past performance is not indicative of future returns. Please consider your specific investment requirements, risk tolerance, investment goal, time frame, risk and reward balance and the cost associated with the investment before choosing a fund, or designing a portfolio that suits your needs.